Current therapies are mostly based on AChE inhibitors (AChEI) to reverse the cholinergic deficit.5 Dual targeted inhibitors of AChE and Aβ aggregation are the main focus of AD paradigm.6 These drugs can be synthesized or harvested from nature, the advantage of the latter being the potential for chemical diversity, biological selectivity and favorable properties. This evidence concerns the gene ACHE and Alzheimer disease.